Search
China Approves Pfizer's Novel Antimicrobial Drug Xifunuo®
1 day ago /
Read about 0 minute
Author：小编
Pfizer has announced the approval of its novel antimicrobial drug, Xifunuo® (Aztreonam Sodium and Avibactam Sodium for Injection), by the National Medical Products Administration of China. This approval allows for the treatment of adult complicated intra-abdominal infections, hospital-acquired pneumonia, and ventilator-associated pneumonia caused by Gram-negative bacteria. As the first β-lactam antibiotic/β-lactamase inhibitor combination to cover all CRE enzyme types, Xifunuo® is pivotal in combating bacterial resistance, holding significant implications for public health and innovative treatment approaches.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
